The PMDA's view on the limited pipeline of nephrology drugs in Japan
Kidney Int
.
2021 Jul;100(1):241-242.
doi: 10.1016/j.kint.2021.03.034.
Authors
Mototsugu Tanaka
1
,
Mutsuhiro Ikuma
2
Affiliations
1
Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Electronic address: motanaka-tky@umin.ac.jp.
2
Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
PMID:
34154711
DOI:
10.1016/j.kint.2021.03.034
No abstract available
Publication types
Letter
Comment
MeSH terms
Drug Approval
Humans
Japan
Kidney Diseases*
Nephrology*
Pharmaceutical Preparations*
Substances
Pharmaceutical Preparations